Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31625100 | 1.00 | KDM4E (0.38) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL38656749 | 0.79 | CDK1 (0.33) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL6901185 | 0.76 | DAPK1 (0.35) | JAK2CDK1 | |
| SCHEMBL28979019 | 0.76 | KMT2A (0.35) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL30677485 | 0.75 | PI4KA (0.50) | ALDH1A1HTTP2RX7 | |
| SCHEMBL16499765 | 0.75 | CYP1A2 (0.33) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL9739976 | 0.74 | ADORA2A (0.40) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL26989021 | 0.74 | KDM4E (0.42) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL30722765 | 0.74 | KDM4E (0.42) | KDM4EJAK2ALDH1A1LMNAHPGD | |
| SCHEMBL24476317 | 0.71 | TSHR (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3934652-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | F-Star Therapeutics, Inc. (GB) | 2022-01-12 | — | — | EP | disclosed |
| CN-113645977-A | Compounds, compositions and methods for treatment of disease | F-星治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-2840083-B1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-09-13 | — | — | EP | disclosed |
| EP-2840083-B1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-09-13 | — | — | EP | disclosed |
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2840083-A1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2840083-A1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157562-A1 | NITROGENATED BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | アステラス製薬株式会社 (JP) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | KDM4E 2351/4885JAK2 2683/4885ALDH1A1 3161/4885 |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | KDM4E 3101/4885JAK2 2770/4885ALDH1A1 3281/4885 |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, CGAS, MAVS | KDM4E 4484/4885JAK2 983/4885ALDH1A1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.